Tag: share

BOSTON, July 24, 2025 (GLOBE NEWSWIRE) -- The Boston Beer Company, Inc. (NYSE: SAM), today reported financial results for the second quarter ended June 28, 2025. Key results were:

HOUSTON, July 24, 2025 (GLOBE NEWSWIRE) -- Archrock, Inc. (NYSE: AROC) (“Archrock” or the “Company”) today announced that its Board of Directors has declared an increased quarterly dividend of $0.21 per share of common stock, or $0.84 per share on an annualized basis. The second quarter 2025 dividend will be paid on August 12, 2025 to all stockholders of record on August 5, 2025.

_{⁽¹⁾ Volume is measured on a standard physical case basis and is used to standardize differing package configurations delivered via direct store delivery.}

RALEIGH, N.C., July 24, 2025 (GLOBE NEWSWIRE) -- Highwoods Properties, Inc. (NYSE:HIW) announces its Board of Directors has declared a cash dividend of $0.50 per share of common stock for the quarter ended June 30, 2025, which equates to an annualized dividend of $2.00 per share. This quarterly dividend is payable on September 9, 2025 to all holders of record as of August 18, 2025.

VERO BEACH, Fla., July 24, 2025 (GLOBE NEWSWIRE) --  (July 24, 2025) – Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid” or the "Company"), a real estate investment trust ("REIT"), today announced results of operations for the three month period ended June 30, 2025.

Investors can contact the law firm at no cost to learn more about recovering their losses

Accesorios Ends Six-Year Stealth Operations, Reveals 150,000-Customer Base Built Through Word-of-Mouth

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global CRISPR Gene Editing Market size & share revenue was valued at approximately USD 3.65 Billion in 2024 and is expected to reach USD 4.10 Billion in 2025 and is expected to reach around USD 12.6 Billion by 2034, at a CAGR of 13.01% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are CRISPR Therapeutics AG, Agilent Technologies Inc., Thermo Fisher Scientific Inc., GeneCopoeia Inc., Synthego Corporation, System Biosciences LLC, ToolGen Inc., Rockland Immunochemicals Inc., Horizon Discovery Group PLC, Abcam Inc., Applied StemCell Inc., Cellecta Inc and others.